4 reports

  • Melanoma
  • PIPELINE BY ONCBIOMUNE PHARMACEUTICALS INC, H2 2017
  • Blood Supply
  • Cancer
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • JUL 20, 2016: PRE-CLINICAL RESEARCH SUPPORTS ADDITIONAL STUDIES OF ONCBIOMUNE TECHNOLOGY FOR BREAST CANCER VACCINE
  • JUL 13, 2016: ONCBIOMUNE SUBMITS PROTOCOL TO INITIATE PHASE 2/3 TRIAL OF PROSCAVAX FOR PROSTATE CANCER
  • Cancer
  • Cytokine
  • Prostate Cancer
  • Vaccine
  • OncBioMune Pharmaceuticals, Inc.
  • ONCBIOMUNE PHARMA AND VITEL LABS FORMS JOINT VENTURE
  • JAN 05, 2016: ONCBIOMUNE ADDS CAPITAL MARKETS LEADER DANIEL HOVERMAN TO BOARD OF DIRECTORS

Its lead product ProscaVax, a therapeutic vaccine is developed for prostate cancer patients; and OvcaVax for treating ovarian cancer.

  • Cancer
  • Mexico
  • United States
  • Company
  • OncBioMune Pharmaceuticals, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2017
  • PIPELINE BY ONCBIOMUNE PHARMACEUTICALS INC, H1 2017
  • Cancer
  • Monoclonal Antibody
  • Prostate Cancer
  • Vaccine
  • OncBioMune Pharmaceuticals, Inc.